HMAI white logo
President’s letter
2020 Metrics
Cycle of Translation
Visionary Gifts
triangle_down.svg
Discovery to Clinic
triangle_down.svg
Innovative Education
triangle_down.svg
Translational Luminaries
Close_Menu.svgSearch.svg
triangle_down.svg
result
Science in Service
of
Medicine
result
President's letter
2020 Metrics
Cycle of Translation
From Discovery to Clinic
Down_arrow.svg
Up_arrow.svg
Translational Luminaries
Close_menu.svg
Discovery to Clinic
Precision Medicine
Can Devices Provide A New Treatment Option for Glioblastoma?
Can Devices Provide A New Treatment Option for Glioblastoma?
Share this story
Experts at the Houston Methodist Kenneth R. Peak Brain & Pituitary Tumor Treatment Center are developing new Glioblastoma multiforme (GBM) treatment options, including an innovative technology that provides anti-cancer therapy through a wearable device.
David S. Baskin, MD
Santosh Helekar, MD, PhD
GBM is the most common and aggressive form of brain cancer. After over 40 years of research, median survival with David S. Baskin, MD Santosh Helekar, MD, PhD aggressive treatment has only improved from 9 to 15 months and the quality of life during this time is often poor.

A team of researchers has developed a new method of generating an oscillating magnetic field (OMF) that eradicates cancer cells via a wearable device. These studies were made possible by the prior invention of a wearable miniaturized multifocal transcranial magnetic stimulator by Santosh Helekar, MD, PhD, associate professor of neurosurgery, and Henning Voss, associate professor of physics in radiology at Weill Cornell Medical College. The device uses microstimulators, called oncoscillators, that rotate strong neodymium permanent magnets devised patterns. Helekar and his colleagues have produced selective anti-cancer effects in patient-derived GBM and breast cancer cells in culture without damaging cultured normal cells.
We believe that our current investigations may help to establish Oncomagnetics as a GBM treatment that does not have the limitations of chemotherapeutic agents. Given that various cancerous cell types are susceptible to apoptosis by OMF-induced accentuation of reactive oxygen species, we hope to modulate our nascent OMF treatment to target other cancers.
David S. Baskin, MD
Kenneth R. Peak Presidential Distinguished Chair of the Department of Neurosurgery, Director of the Brain Metastasis, Glial Tumor and Pituitary Tumor and Disorder Initiative
On a cellular level, they demonstrated that when OMFs are applied in a defined pattern at a certain range of frequencies, they disrupt electron flows in the mitochondrial electron transport chain that drives cellular fuel production. This disruption leads to the generation of reactive oxygen species, triggering a cascade of cellular events that leads to cancer cell apoptosis. Compared with normal cells of the same tissue type, cancer cells have critically high levels of reactive oxygen species at baseline that are poised to trigger apoptosis if further increased.

With this information, the investigators further optimized the stimulus parameters of OMF stimulation and confirmed safety and efficacy in a humanized preclinical model of GBM. They then modified the Helekar-Voss Transcranial Permanent Magnet Stimulator device to construct a wearable device prototype for humans called an Oncomagnetic Device along with the associated hardware, software and mobile device applications.
Share this story